patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_266878 | REC_0014301 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.2 | 68 | female | 1 | 18 | 4.4 | 3 | sotorasib 960 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:36:00.725005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350253 | REC_0014302 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 14 | 13.8 | 69 | female | 1 | 16 | 4.5 | 1 | osimertinib 80 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:36:00.725379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847611 | REC_0014303 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15.5 | 74 | female | 2 | 17 | 5.6 | 5 | entrectinib 600 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:00.725718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120581 | REC_0014304 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.2 | 71 | female | 2 | 18 | 5.1 | 8 | alectinib 600 mg BID | 10.2 | true | MSS | 2026-03-15T05:36:00.726060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354851 | REC_0014305 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.3 | 70 | female | 2 | 19 | 6.1 | 9 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:00.726398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183673 | REC_0014306 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 5.5 | 64 | female | 0 | 18 | 5.9 | 8 | osimertinib 80 mg daily | 7.9 | false | MSS | 2026-03-15T05:36:00.726737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618579 | REC_0014307 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.6 | 69 | female | 1 | 56 | 2.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:36:00.727080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856247 | REC_0014308 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.1 | 70 | female | 2 | 1 | 4.7 | 8 | pembrolizumab 200 mg q3w | 7.1 | false | MSS | 2026-03-15T05:36:00.727453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688232 | REC_0014309 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.2 | 79 | male | 2 | 27 | 4.8 | 9 | sotorasib 960 mg daily | 4.4 | false | MSS | 2026-03-15T05:36:00.727821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218287 | REC_0014310 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.8 | 65 | male | 0 | 47 | 8.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:00.728675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192844 | REC_0014311 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.3 | 78 | female | 2 | 11 | 5.7 | 6 | sotorasib 960 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:36:00.729139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863880 | REC_0014312 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 15.1 | 56 | male | 1 | 12 | 6.4 | 7 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:36:00.729612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136583 | REC_0014313 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.7 | 58 | male | 0 | 10 | 5.1 | 8 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:00.730037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678026 | REC_0014314 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 20.2 | 64 | female | 0 | 19 | 7.1 | 6 | osimertinib 80 mg daily | 17.9 | false | MSS | 2026-03-15T05:36:00.730671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864051 | REC_0014315 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 10.1 | 59 | male | 1 | 13 | 5.7 | 1 | entrectinib 600 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:36:00.731137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378499 | REC_0014316 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.3 | 72 | female | 1 | 20 | 7.8 | 5 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:36:00.734098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908794 | REC_0014317 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 8.1 | 74 | female | 1 | 15 | 7.4 | 1 | alectinib 600 mg BID | 18.7 | false | MSS | 2026-03-15T05:36:00.734646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235676 | REC_0014318 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.4 | 65 | female | 1 | 15 | 6.3 | 1 | osimertinib 80 mg daily | 25.6 | false | MSS | 2026-03-15T05:36:00.736059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941346 | REC_0014319 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 5 | 66 | female | 0 | 11 | 4.2 | 0 | osimertinib 80 mg daily | 24.5 | false | MSS | 2026-03-15T05:36:00.736563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964322 | REC_0014320 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.4 | 61 | female | 1 | 6 | 7.1 | 2 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.736961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232082 | REC_0014321 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.5 | 75 | female | 1 | 18 | 8.2 | 2 | sotorasib 960 mg daily | 20.2 | false | MSS | 2026-03-15T05:36:00.737312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826879 | REC_0014322 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.3 | 63 | female | 0 | 6 | 6.4 | 7 | sotorasib 960 mg daily | 6.3 | false | MSS | 2026-03-15T05:36:00.737651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422671 | REC_0014323 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.8 | 60 | male | 1 | 22 | 5.1 | 5 | sotorasib 960 mg daily | 5 | true | MSS | 2026-03-15T05:36:00.738001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347081 | REC_0014324 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 14.5 | 68 | female | 1 | 11 | 4.7 | 1 | osimertinib 80 mg daily | 21.6 | true | MSS | 2026-03-15T05:36:00.738352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720078 | REC_0014325 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 4.6 | 68 | female | 0 | 14 | 4.2 | 1 | sotorasib 960 mg daily | 18 | true | MSS | 2026-03-15T05:36:00.738747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248488 | REC_0014326 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.8 | 74 | female | 2 | 18 | 6.1 | 5 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:36:00.739158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128823 | REC_0014327 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.6 | 82 | female | 2 | 13 | 5.6 | 5 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.739810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409084 | REC_0014328 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 18.1 | 66 | male | 1 | 21 | 6.3 | 2 | alectinib 600 mg BID | 33.5 | true | MSS | 2026-03-15T05:36:00.740377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797366 | REC_0014329 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 18.9 | 73 | female | 2 | 25 | 5.7 | 1 | entrectinib 600 mg daily | 20.6 | false | MSI-H | 2026-03-15T05:36:00.740929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569787 | REC_0014330 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.7 | 64 | male | 0 | 8 | 6.5 | 7 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:00.741399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817906 | REC_0014331 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 6.6 | 73 | female | 2 | 20 | 5.2 | 3 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:36:00.741884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850222 | REC_0014332 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.5 | 71 | female | 3 | 35 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:36:00.742381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817477 | REC_0014333 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.5 | 68 | female | 1 | 20 | 5.5 | 2 | alectinib 600 mg BID | 10.1 | true | MSI-H | 2026-03-15T05:36:00.742866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654238 | REC_0014334 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 20.5 | 79 | female | 2 | 18 | 5.6 | 8 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:36:00.743312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582223 | REC_0014335 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 36 | 4.1 | 60 | female | 1 | 33 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.4 | false | MSS | 2026-03-15T05:36:00.743753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147477 | REC_0014336 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.4 | 65 | female | 0 | 21 | 5.5 | 2 | entrectinib 600 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:00.744237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535659 | REC_0014337 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.3 | 64 | female | 1 | 23 | 5.8 | 9 | osimertinib 80 mg daily | 5.5 | false | MSI-H | 2026-03-15T05:36:00.744690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670122 | REC_0014338 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.3 | 68 | female | 1 | 28 | 4.8 | 4 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:36:00.745090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756173 | REC_0014339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 1.5 | 66 | female | 1 | 15 | 6.2 | 7 | entrectinib 600 mg daily | 4.4 | false | MSS | 2026-03-15T05:36:00.745464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372608 | REC_0014340 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.7 | 57 | female | 1 | 45 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | true | MSS | 2026-03-15T05:36:00.746102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957524 | REC_0014341 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 10.1 | 65 | female | 1 | 30 | 4.1 | 7 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:36:00.746588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457596 | REC_0014342 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.2 | 83 | female | 2 | 24 | 5.5 | 5 | pembrolizumab 200 mg q3w | 14.5 | true | MSI-H | 2026-03-15T05:36:00.747047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736620 | REC_0014343 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 17 | 65 | male | 1 | 10 | 5.7 | 5 | pembrolizumab 200 mg q3w | 8.4 | true | MSS | 2026-03-15T05:36:00.747516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773097 | REC_0014344 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.7 | 56 | female | 0 | 11 | 5.1 | 2 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.747957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714249 | REC_0014345 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.4 | 50 | female | 0 | 39 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:36:00.751282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951186 | REC_0014346 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.7 | 72 | female | 2 | 16 | 7 | 2 | osimertinib 80 mg daily | 20.3 | false | MSI-H | 2026-03-15T05:36:00.751851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710886 | REC_0014347 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.3 | 70 | female | 3 | 15 | 3.9 | 4 | osimertinib 80 mg daily | 19.2 | true | MSI-H | 2026-03-15T05:36:00.753228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202270 | REC_0014348 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.8 | 74 | female | 2 | 13 | 7.3 | 2 | osimertinib 80 mg daily | 17.5 | true | MSS | 2026-03-15T05:36:00.753677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109701 | REC_0014349 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.2 | 78 | female | 2 | 36 | 5.1 | 6 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:36:00.754052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110741 | REC_0014350 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 19.6 | 81 | female | 3 | 23 | 6.6 | 10 | osimertinib 80 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:36:00.754427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784363 | REC_0014351 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.7 | 69 | male | 0 | 17 | 6.7 | 6 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:36:00.754776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957688 | REC_0014352 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.9 | 44 | male | 0 | 27 | 4.1 | 1 | pembrolizumab 200 mg q3w | 28.5 | false | MSS | 2026-03-15T05:36:00.755123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154370 | REC_0014353 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 14.5 | 78 | male | 2 | 26 | 5.5 | 5 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:36:00.755643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370369 | REC_0014354 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 7.3 | 80 | female | 2 | 51 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.5 | true | MSS | 2026-03-15T05:36:00.755972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286591 | REC_0014355 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 11.9 | 72 | male | 2 | 5 | 8.9 | 0 | alectinib 600 mg BID | 53 | true | MSS | 2026-03-15T05:36:00.756744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609809 | REC_0014356 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.9 | 67 | female | 1 | 21 | 4.4 | 7 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.757231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306040 | REC_0014357 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8.4 | 67 | female | 0 | 17 | 4.9 | 2 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:36:00.757620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898990 | REC_0014358 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10.2 | 70 | female | 0 | 19 | 3.5 | 2 | pembrolizumab 200 mg q3w | 13.1 | false | MSI-H | 2026-03-15T05:36:00.757976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194386 | REC_0014359 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.7 | 64 | female | 0 | 15 | 6.7 | 1 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:00.758314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923709 | REC_0014360 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.3 | 69 | female | 1 | 10 | 5.1 | 2 | osimertinib 80 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:36:00.758986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829733 | REC_0014361 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 16 | 14.6 | 67 | female | 0 | 13 | 4.8 | 1 | pembrolizumab 200 mg q3w | 8.3 | true | MSI-H | 2026-03-15T05:36:00.759402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434466 | REC_0014362 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10.4 | 74 | female | 1 | 7 | 5.2 | 2 | sotorasib 960 mg daily | 19.5 | true | MSI-H | 2026-03-15T05:36:00.759736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621785 | REC_0014363 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.3 | 64 | male | 0 | 51 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:36:00.760123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760616 | REC_0014364 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.1 | 55 | male | 0 | 86 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.3 | true | MSS | 2026-03-15T05:36:00.760505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796192 | REC_0014365 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 6.8 | 64 | female | 0 | 12 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:00.760883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166424 | REC_0014366 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 7.5 | 57 | male | 1 | 12 | 7.2 | 5 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:00.761426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786886 | REC_0014367 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 16.9 | 70 | female | 2 | 11 | 7.5 | 3 | entrectinib 600 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:00.761841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712160 | REC_0014368 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 9.1 | 72 | female | 1 | 51 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:36:00.762495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737931 | REC_0014369 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9.1 | 73 | female | 2 | 20 | 5.7 | 4 | sotorasib 960 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:00.762966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610894 | REC_0014370 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 14 | 71 | female | 2 | 18 | 5 | 2 | alectinib 600 mg BID | 22.9 | true | MSI-H | 2026-03-15T05:36:00.763317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777253 | REC_0014371 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.1 | 67 | male | 1 | 45 | 7.4 | 6 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:36:00.763660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609912 | REC_0014372 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.2 | 64 | male | 1 | 20 | 3.4 | 6 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:00.763999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646040 | REC_0014373 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 12.1 | 67 | male | 1 | 10 | 5.3 | 1 | entrectinib 600 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:00.764436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170869 | REC_0014374 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.2 | 66 | male | 0 | 14 | 5.9 | 5 | osimertinib 80 mg daily | 15.9 | true | MSI-H | 2026-03-15T05:36:00.764761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817749 | REC_0014375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.9 | 67 | female | 0 | 7 | 4 | 5 | entrectinib 600 mg daily | 6 | true | MSI-H | 2026-03-15T05:36:00.765086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528453 | REC_0014376 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 12.7 | 76 | male | 0 | 17 | 4.5 | 4 | entrectinib 600 mg daily | 16.9 | false | MSS | 2026-03-15T05:36:00.765456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453489 | REC_0014377 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.3 | 70 | female | 2 | 11 | 6.4 | 7 | entrectinib 600 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:00.765816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645437 | REC_0014378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 7.3 | 64 | male | 1 | 16 | 6.7 | 0 | alectinib 600 mg BID | 21.5 | false | MSS | 2026-03-15T05:36:00.766180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989090 | REC_0014379 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.8 | 72 | female | 2 | 17 | 3 | 1 | pembrolizumab 200 mg q3w | 5.4 | true | MSS | 2026-03-15T05:36:00.766694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284411 | REC_0014380 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.7 | 69 | female | 0 | 13 | 4.5 | 4 | osimertinib 80 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:36:00.767053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826246 | REC_0014381 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.1 | 71 | male | 1 | 12 | 7.5 | 2 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.767402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822830 | REC_0014382 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15.9 | 68 | female | 1 | 11 | 6.4 | 4 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.767748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254966 | REC_0014383 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 8 | 73 | female | 2 | 4 | 4.5 | 5 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:00.768162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188898 | REC_0014384 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 30 | 4.7 | 64 | female | 1 | 13 | 4.8 | 0 | pembrolizumab 200 mg q3w | 42.4 | false | MSS | 2026-03-15T05:36:00.768548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713192 | REC_0014385 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 8.9 | 78 | female | 1 | 47 | 6.1 | 7 | pembrolizumab 200 mg q3w | 14.3 | true | MSS | 2026-03-15T05:36:00.768903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142918 | REC_0014386 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13.5 | 68 | female | 1 | 21 | 5.3 | 9 | sotorasib 960 mg daily | 5.1 | false | MSI-H | 2026-03-15T05:36:00.769239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150388 | REC_0014387 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.3 | 66 | female | 0 | 16 | 5.5 | 6 | osimertinib 80 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:00.769601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579446 | REC_0014388 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.3 | 67 | male | 0 | 57 | 6.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:36:00.769943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222795 | REC_0014389 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.7 | 71 | male | 0 | 15 | 3.9 | 3 | alectinib 600 mg BID | 8.1 | false | MSS | 2026-03-15T05:36:00.770280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604434 | REC_0014390 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.9 | 58 | male | 0 | 47 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 15 | false | MSS | 2026-03-15T05:36:00.770599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781000 | REC_0014391 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 14.9 | 59 | male | 1 | 15 | 6.7 | 5 | osimertinib 80 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:36:00.770945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394492 | REC_0014392 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 7.2 | 55 | female | 0 | 65 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.2 | false | MSS | 2026-03-15T05:36:00.771458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236540 | REC_0014393 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 12 | 6.7 | 71 | female | 2 | 13 | 3.9 | 4 | sotorasib 960 mg daily | 10.4 | false | MSS | 2026-03-15T05:36:00.771854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769321 | REC_0014394 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15 | 83 | female | 2 | 21 | 4.8 | 6 | sotorasib 960 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:00.772320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196426 | REC_0014395 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.2 | 60 | female | 1 | 24 | 4.3 | 2 | entrectinib 600 mg daily | 28.3 | true | MSS | 2026-03-15T05:36:00.772722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535233 | REC_0014396 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.8 | 76 | female | 1 | 20 | 4.4 | 5 | osimertinib 80 mg daily | 7.3 | false | MSS | 2026-03-15T05:36:00.773132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309540 | REC_0014397 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.5 | 74 | male | 2 | 2 | 3.7 | 2 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.773540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699264 | REC_0014398 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 9.1 | 73 | male | 2 | 12 | 6.1 | 4 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:36:00.773927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590420 | REC_0014399 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 12.9 | 65 | male | 1 | 10 | 5.5 | 1 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:36:00.774325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747431 | REC_0014400 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 20.1 | 72 | female | 1 | 15 | 6 | 2 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:00.774714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.